Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?

Key Takeaways IRWD expects 2026 revenues of $450-$475 million, reflecting strong Linzess sales momentum.Ironwood recorded $244.1 million in Linzess net profit share during the first nine months of 2025.Linzess price cuts and underlying demand are expected to support wider adoption in 2026.Ironwood Pharmaceuticals (IRWD) has been witnessing improved demand for its sole marketed product, Linzess (linaclotide), in recent quarters. The company markets Linzess in the United States in collaboration with drug gian ...